Pfizer’s LITFULO cleared a major Phase 3 hurdle in vitiligo, but the missing numbers could decide its future
Pfizer’s Phase 3 LITFULO vitiligo results strengthen its filing case, but dose, safety and durability details remain decisive.
Pharma & Biotech